Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
Click Here if you want to upgrade your account
If you were able to post but cannot do so now, send an email to admin at raypeatforum dot com and include your username and we will fix that right up for you.
Abstract
Over the past several decades, the incidence of early-onset cancers, often defined as cancers diagnosed in adults <50 years of age, in the breast, colorectum, endometrium, oesophagus, extrahepatic bile duct, gallbladder, head and neck, kidney, liver, bone marrow, pancreas, prostate, stomach and thyroid has increased in multiple countries. Increased use of screening programmes has contributed to this phenomenon to a certain extent, although a genuine increase in the incidence of early-onset forms of several cancer types also seems to have emerged. Evidence suggests an aetiological role of risk factor exposures in early life and young adulthood. Since the mid-20th century, substantial multigenerational changes in the exposome have occurred (including changes in diet, lifestyle, obesity, environment and the microbiome, all of which might interact with genomic and/or genetic susceptibilities). However, the effects of individual exposures remain largely unknown. To study early-life exposures and their implications for multiple cancer types will require prospective cohort studies with dedicated biobanking and data collection technologies. Raising awareness among both the public and health-care professionals will also be critical. In this Review, we describe changes in the incidence of early-onset cancers globally and suggest measures that are likely to reduce the burden of cancers and other chronic non-communicable diseases.
Key points
The incidence of cancers of various organs diagnosed in adults ≤50 years of age has been rising in many parts of the world since the 1990s.
Evidence suggests an aetiological role for risk factor exposures in early life and young adulthood, although specific effects of individual exposures remain largely unknown.
The early life exposome (including, among other factors, diet, lifestyle, obesity, environmental exposures and the microbiome) has changed substantially, with variable trends observed around the world since the mid-20th century.
The early-onset cancer epidemic might be one manifestation of increasing trends in the development of many chronic diseases in young and future generations.
Prospective cohort studies using electronic health records and/or early-life biospecimen collection would enable the detailed investigation of early-life factors in relation to many future health outcomes, including cancer.
Raising awareness of the early-onset cancer epidemic and improving the early-life environment should be our immediate goals: these are likely to reduce the burden of both early-onset and later-onset cancers.
unbelievable! putting it out there right in front of us...
dont forget pfizer bought a drug company that just so happens to make heart medications....
Pfizer buys pharmaceutical company that makes heart medication to solve the problem caused by mRNA vaccines
Big Pharma company Pfizer recently bought another pharmaceutical company specializing in producing heart medication. Coincidentally, some of these heart medications can counteract the heart problems caused by Pfizer’s Wuhan coronavirus (COVID-19) mRNA vaccine. Pfizer recently signed an agreement...www.vaccinedeaths.com